Skip to content
Open access

Association of IL-6 and IL-10 serum levels with genetic variants in diabetic neuropathy: Clinical findings from a Bangladeshi patient cohort

Oct 2026 · PLoS ONE · Vol 21 · 0 citations · 46 references
Medicine

Abstract

Background Diabetic Neuropathy (DN) is a prevalent complication of diabetes linked to chronic inflammation. Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are key cytokines implicated in DN pathogenesis. This study investigates the association of IL6 and IL10 gene polymorphisms and serum levels with DN in the Bangladeshi population. Materials and methods A case-control study was conducted with 225 participants: diabetic patients with DN (n = 75), diabetic patients without DN (n = 75), and healthy controls (n = 75). Genomic DNA was extracted for genotyping IL-6 (rs1800796) and IL-10 (rs1800896) SNPs via PCR. Serum cytokine levels were measured using ELISA. Results Serum IL-6 levels were significantly higher in the DN group than in the other study groups (p < 0.0001), with the highest levels observed among individuals with the IL-6 rs1800796 CC genotype. In unadjusted analyses, the IL-6 CC genotype was associated with increased odds of DN compared with healthy controls (OR = 4.813, 95% CI: 1.752–13.85, p = 0.0040), as was the IL-10 GG genotype (OR = 2.679, 95% CI: 1.000–6.751, p = 0.0373). However, neither IL-6 nor IL-10 genotype remained independently associated with DN after multivariable adjustment. Serum IL-10 levels did not differ significantly among the study groups (p = 0.0948). Combined genotype analyses showed several nominal associations, although these findings were exploratory. Serum IL-6 showed promising discriminatory ability in distinguishing patients with DN from the other study groups, whereas IL-10 demonstrated limited discriminatory performance. Conclusion These findings support further investigation of serum IL-6 as a potential candidate biomarker for diabetic neuropathy, whereas the independent contribution of the investigated IL-6 and IL-10 polymorphisms remains uncertain. Larger prospective studies with independent external validation are required before clinical application can be considered.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.